|
related topics |
{condition, economic, financial} |
{regulation, government, change} |
{customer, product, revenue} |
{system, service, information} |
{regulation, change, law} |
{product, liability, claim} |
{product, market, service} |
{acquisition, growth, future} |
{control, financial, internal} |
{operation, international, foreign} |
{cost, contract, operation} |
|
Intense competition as well as industry consolidations may erode our profit margins.
Our results of operations continue to be subject to the risks and uncertainties of inflation in branded pharmaceutical prices and deflation in generic pharmaceutical prices.
Declining economic conditions could adversely affect our results of operations and financial condition.
Our stock price and our ability to access credit markets may be adversely affected by the current levels of financial market volatility and disruption, which are unprecedented.
Our total revenue and results of operations may suffer upon the loss of a significant customer.
Our total revenue and results of operations may suffer upon the bankruptcy, insolvency or other credit failure of a significant customer.
Our results of operations may suffer upon the bankruptcy, insolvency or other credit failure of a significant supplier.
Increasing governmental efforts to regulate the pharmaceutical supply channel may increase our costs and reduce our profitability.
The suspension or revocation by the DEA of any of the registrations that must be in effect for our distribution facilities to purchase, store and distribute controlled substances or the refusal by DEA to issue a registration to any such facility that requires such registration may adversely affect our reputation, our business and our results of operations.
Legal and regulatory changes reducing reimbursement rates for pharmaceuticals and/or medical treatments or services may reduce our profitability and adversely affect our business and results of operations.
The changing United States healthcare environment may negatively impact our business and our profitability.
If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations.
Our results of operations and financial condition may be adversely affected if we undertake acquisitions of businesses that do not perform as we expect or that are difficult for us to integrate.
Our results of operations and our financial condition may be adversely affected by foreign operations.
Risks generally associated with our sophisticated information systems may adversely affect our business and results of operations.
Risks generally associated with implementation of an enterprise resource planning (ERP) system may adversely affect our business and results of operations or the effectiveness of internal control over financial reporting.
Tax legislation initiatives or challenges to our tax positions could adversely affect our results of operations and financial condition.
Full 10-K form ▸
|
|
related documents |
1140859--11/23/2010--AMERISOURCEBERGEN_CORP |
920527--5/23/2008--PSS_WORLD_MEDICAL_INC |
920527--5/26/2010--PSS_WORLD_MEDICAL_INC |
78749--6/9/2009--AGILYSYS_INC |
920527--5/20/2009--PSS_WORLD_MEDICAL_INC |
856982--3/10/2010--MERIT_MEDICAL_SYSTEMS_INC |
821026--2/26/2010--ANDERSONS_INC |
764858--9/27/2007--FOUNTAIN_POWERBOAT_INDUSTRIES_INC |
723612--3/1/2006--CENDANT_CORP |
29989--2/27/2009--OMNICOM_GROUP_INC |
1140859--11/28/2007--AMERISOURCEBERGEN_CORP |
97216--2/28/2007--TEREX_CORP |
49071--2/20/2009--HUMANA_INC |
720671--6/30/2009--HALIFAX_CORP_OF_VIRGINIA |
949874--3/12/2009--YOUNG_INNOVATIONS_INC |
764401--11/30/2010--INSTEEL_INDUSTRIES_INC |
918581--3/6/2008--CIBER_INC |
949874--3/14/2006--YOUNG_INNOVATIONS_INC |
949874--3/15/2007--YOUNG_INNOVATIONS_INC |
949874--3/14/2008--YOUNG_INNOVATIONS_INC |
97216--2/27/2008--TEREX_CORP |
852426--3/29/2006--PW_EAGLE_INC |
320121--5/23/2006--TELOS_CORP |
33113--5/12/2009--ENVIRONMENTAL_TECTONICS_CORP |
40533--2/19/2010--GENERAL_DYNAMICS_CORP |
745394--3/16/2007--LESCO_INC/OH |
57139--8/28/2009--LABARGE_INC |
822663--3/15/2006--INTER_PARFUMS_INC |
97216--5/17/2006--TEREX_CORP |
1099800--2/26/2010--Edwards_Lifesciences_Corp |
|